Bedoradrine sulfate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529534

CAS#: 194785-31-4 (sulfate)

Description: Bedoradrine sulfate is a β2-adrenoceptor agonist potentially for the treatment of asthma.

Chemical Structure

img
Bedoradrine sulfate
CAS# 194785-31-4 (sulfate)
Instruction

Theoretical Analysis

MedKoo Cat#: 529534
Name: Bedoradrine sulfate
CAS#: 194785-31-4 (sulfate)
Chemical Formula: C24H34N2O9S
Exact Mass: 0.00
Molecular Weight: 526.601
Elemental Analysis: C, 54.74; H, 6.51; N, 5.32; O, 27.34; S, 6.09

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 194785-19-8 (free base)   194785-31-4 (sulfate)   1338644-26-0 (fumarate)   1338644-30-6 (mesylate)    

Synonym: Bedoradrine sulfate; Bedoradrine; MN-221; KUR-1246; MN221; KUR1246; MN 221; KUR 1246

IUPAC/Chemical Name: 2-(((S)-7-(((R)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)-N,N-dimethylacetamide sulfate

InChi Key: BIBSCYWSUFOPGZ-WCRWPNQISA-N

InChi Code: InChI=1S/C24H32N2O5.H2O4S/c1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t20-,23-;/m0./s1

SMILES Code: O=C(N(C)C)COC1=CC=C2CC[C@H](NC[C@H](O)C3=CC=C(O)C(CCO)=C3)CC2=C1.O=S(O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 526.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Matsuda K, Makhay M, Johnson K, Iwaki Y. Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion. J Asthma. 2012 Dec;49(10):1071-8. doi: 10.3109/02770903.2012.729631. PubMed PMID: 23094708.

2: House SL, Matsuda K, O'Brien G, Makhay M, Iwaki Y, Ferguson I, Lovato LM, Lewis LM. Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma. Respir Med. 2015 Oct;109(10):1268-73. doi: 10.1016/j.rmed.2015.08.003. PubMed PMID: 26324315.

3: Antoniu S. Bedoradrine for treating asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014 Aug;23(8):1149-56. doi: 10.1517/13543784.2014.928284. Review. PubMed PMID: 24938936.

4: Inoue Y, Yoshizato T, Kawarabayashi T. Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13. doi: 10.1111/j.1447-0756.2008.01001.x. PubMed PMID: 19527375.

5: Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010179. doi: 10.1002/14651858.CD010179. Review. PubMed PMID: 23235685.

6: Gross N. The COPD pipeline XX. COPD. 2013 Feb;10(1):104-6. doi: 10.3109/15412555.2013.766103. PubMed PMID: 23413896.

7: Furihata Y, Kobayashi M, Kojima M, Kobayashi K, Kawarabayashi T, Yamamoto T. Effects of KUR-1246, a selective uterine relaxant, on transplacental passage and transmigration to milk. J Obstet Gynaecol Res. 2006 Feb;32(1):4-9. PubMed PMID: 16445519.

8: Furihata Y, Motokawa Y, Murata S, Kiguchi S, Kobayashi M, Murakami M, Kojima M, Yamamoto T. Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant. Arzneimittelforschung. 2006;56(1):18-24. PubMed PMID: 16478001.

9: Murata S, Matsuda T, Kiguchi S, Kobayashi M, Cho K, Okuyama K. Effects of long term administration of KUR-1246, a selective beta(2)-adrenoceptor agonist, on pregnant sheep and their fetuses. BJOG. 2005 Jan;112(1):69-74. PubMed PMID: 15663400.

10: Kiguchi S, Matsuda T, Cho K, Okuyama K, Akahane M, Fujimoto S. KUR-1246, a novel beta(2)-adrenoceptor agonist, as a tocolytic agent. Obstet Gynecol. 2002 Sep;100(3):487-94. PubMed PMID: 12220768.

11: Sakakibara T, Inoue Y, Uzue S, Tsukamoto T, Kobayashi M, Kojima M, Akahane M, Kitamura K, Kawarabayashi T. Diversity of inhibitory responses to beta2-stimulants shown by term-pregnant human myometria in vitro is partly due to differences in receptor density. Am J Obstet Gynecol. 2002 May;186(5):997-1004. PubMed PMID: 12015527.

12: Yanagi T, Kikuchi K, Takeuchi H, Ishikawa T, Nishimura T, Yamamoto I. The practical synthesis of a uterine relaxant, bis(2-[[(2S)-2-([(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)-phenyl]ethyl]amin o)-1,2,3,4-tetrahydronaphthalen-7-yl]oxy]-N,N-dimethylacetamide) sulfate (KUR-1246). Chem Pharm Bull (Tokyo). 2001 Aug;49(8):1018-23. PubMed PMID: 11515570.

13: Kobayashi M, Takeda K, Murata S, Kojima M, Akahane M, Inoue Y, Kitamura K, Kawarabayashi T. Pharmacological characterization of KUR-1246, a selective uterine relaxant. J Pharmacol Exp Ther. 2001 May;297(2):666-71. PubMed PMID: 11303056.